GC
SVNT

Guggenheim Capital’s SAVIENT PHARMACEUTICALS INC SVNT Stock Holding History

Guggenheim Capital’s Portfolio SVNT Stock Details SVNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-28,310
Closed -$18K – 3379
2013
Q3 		$18K Buy
28,310
+7,667
+37% +$4.91K ﹤0.01% 3026
2013
Q2 		$12K Buy
+20,643
New +$14.4K ﹤0.01% 3010

Other funds holding SVNT

Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
FHC
First Heartland Consultants Lake St. Louis, Missouri $1.55B AUM 20.5% 1-Year Est. Return
PSC
Prentiss Smith & Co Brattleboro, Vermont $172M AUM 21.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Guggenheim Capital's SVNT Position: Q4 2013 in Review

Guggenheim Capital sold out of SAVIENT PHARMACEUTICALS INC (SVNT) in Q4 2013, closing a stake of 28,310 shares — an estimated $18K sold.

Guggenheim Capital first reported a position in SVNT in Q2 2013 and held it in 2 quarters. The position peaked at $18K in Q3 2013. 7 funds tracked by Wall St. Rank hold SVNT as of Q4 2013.

  • Guggenheim Capital reported no remaining SAVIENT PHARMACEUTICALS INC position as of Q4 2013 after selling out during the quarter.
  • Guggenheim Capital sold 28,310 SAVIENT PHARMACEUTICALS INC shares in Q4 2013, an estimated $18K.
  • Guggenheim Capital first reported a position in SAVIENT PHARMACEUTICALS INC in Q2 2013 and held it in 2 quarters.
  • Guggenheim Capital's SAVIENT PHARMACEUTICALS INC position peaked at $18K in Q3 2013.
  • 7 funds tracked by Wall St. Rank held SAVIENT PHARMACEUTICALS INC as of Q4 2013.

Based on Guggenheim Capital's 13F filing for Q4 2013, filed 14 Feb 2014.